Clinical trial
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
NCT03023319
Study timeline
Study start (actual)2019-12-10Date precision: day
Registry last updated2022-06-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Mesotheliomaunresolved
Bladder Cancerunresolved
Ovarian Cancerunresolved
Peritoneal Cancerunresolved
Thymomaunresolved
Thymus Cancerunresolved
Uterine Cervical Cancerunresolved
Interventions
BosutinibDRUG · verified · RxNorm: bosutinib
PemetrexedDRUG · verified · RxNorm: pemetrexed
Sponsors & collaborators
Nagla Abdel Karimlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03023319 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.